CRISPR Therapeutics AG — Director's Dealing 2021

Jan 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-01-02

Reporting Person: Klein Lawrence Otto (CBO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-02	Common Shares	F	9392	$153.11	Disposed	10608	Direct

Footnotes

F1: On January 2, 2019, the reporting person was granted 20,000 restricted stock units. The restricted stock units vested in full on January 2, 2021. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.